Long term survival with the combination of interferon and chemotherapy in metastatic melanoma

The prognosis of metastatic melanoma is poor. Pre-targeted treatment era, the combination of interferon-α (IF-α) plus chemotherapy had been used and have generally short response duration. Herein, we present a metastatic melanoma case that achieved long-term durable complete response (CR) IF-α plus...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Egyptian National Cancer Institute Vol. 27; no. 3; pp. 161 - 163
Main Authors: Karagöz, Bülent, Bilgi, Oğuz, Özgün, Alpaslan, Emirzeoğlu, Levent, Çelik, Serkan, Özet, Ahmet
Format: Journal Article
Language:English
Published: Cairo, Egypt Elsevier B.V 01-09-2015
Cairo University, National Cancer Institute
SpringerOpen
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The prognosis of metastatic melanoma is poor. Pre-targeted treatment era, the combination of interferon-α (IF-α) plus chemotherapy had been used and have generally short response duration. Herein, we present a metastatic melanoma case that achieved long-term durable complete response (CR) IF-α plus chemotherapy and IF-α maintenance therapy and had lower Regulatory T (Treg) cells. A fifty-year old woman was admitted to the hospital with metastatic melanoma. Lactate dehydrogenase (LDH) level was 660U/L. The percentage of CD4+CD25+ Treg cells was 2.4% in CD4+ lymphocytes. The IF-α plus chemotherapy and IF-α maintenance were administered. After six courses of chemotherapy, CR was achieved. Vitiligo and hypothyroidism occurred. The patient has remained in CR for approximately 7years until second pleural metastases were detected and death. The patient has positive prognostic factors such as induction of autoimmunity, small tumor volume, mild elevated LDH level, and lower Treg cell percentage. She survived long term with CR after IF-α treatment with concurrent chemotherapy and maintenance. IF-α plus chemotherapy may be a treatment option for metastatic melanoma in selected cases who cannot reach new targeted drugs.
ISSN:1110-0362
1687-9996
2589-0409
DOI:10.1016/j.jnci.2015.02.004